Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB. RB showed excellent efficacy and survival and less toxicity compared with a cytarabine-based regimen in transplant-eligible MCL patients.

Na minha lista:
書目詳細資料
發表在:Blood Adv
Main Authors: Kamdar, Manali, Li, Hongli, Chen, Robert W., Rimsza, Lisa M., Leblanc, Michael L., Fenske, Timothy S., Shea, Thomas C., Barr, Paul M., Phillips, Tycel J., Leonard, John P., Kahl, Brad S., Friedberg, Jonathan W., Smith, Sonali M.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2019
主題:
Stimulus Report
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849956/
https://ncbi.nlm.nih.gov/pubmed/31648328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000526
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍